Obesity Drugs: Stocks to Watch
George Budwell, The Motley Fool - Motley Fool - Tue Jun 09, 10:06AM CDT
Obesity is a big healthcare problem. In the U.S. alone, an estimated 35% of adults, or 85 million people, are believed to be obese, putting them at increased risk of certain forms of cancer, cardiovascular disease, and type 2 diabetes, among many...
OREX: 4.70 (+0.04), ARNA: 4.29 (+0.04)
Asco - A Sirius Lead For Daratumumab
EP Vantage - at Seeking Alpha - Mon Jun 01, 12:16PM CDT
G enmab ( OTCPK:GMXAY , OTC:GNMSF investors celebrated earlier this month when Johnson & Johnson (NYSE: JNJ ) said it would file its partnered multiple myeloma project daratumumab this year based on the phase II Sirius study. Recently...
JNJ: 99.53 (+1.13), CELG: 118.84 (+1.97)
Synergy: This Popular Biotech Is Approaching A Major Clinical Event, Here's How To Trade It
Lowenthal Capital Partners - at Seeking Alpha - Sat May 30, 12:05PM CDT
SGYP: 9.13 (+0.49), IRWD: 11.44 (-0.06)
Orexigen Therapeutics, Inc. Goes From Biotech Beauty to Dreadful Drugmaker
Brian Orelli, The Motley Fool - Motley Fool - Sat May 16, 10:04AM CDT
Orexigen Therapeutics has been the darling of the obesity drugmakers, doing something Arena Pharmaceuticals and VIVUS weren't able to do: keep its share price above where it was when its weight-loss drug was approved in September. ...
OREX: 4.70 (+0.04), VVUS: 2.15 (+0.02), ARNA: 4.29 (+0.04)
Seeking Alpha's Biotech Weekly: Orexigen's Wreck, Stagnant Gilead, And More
SA Editor Mike Taylor - Seeking Alpha - Fri May 15, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors weighed the options for Orexigen (NASDAQ: OREX ) after the...
PRGO: 180.86 (+0.85), VRTX: 122.95 (+2.06), OVAS: 27.28 (+0.82), MYL: 71.22 (+0.87), AMGN: 154.10 (+2.79), GSK: 42.45 (+0.65), ALR: 52.77 (+0.40), ONTY: 3.66 (+0.04), CELG: 118.84 (+1.97), PVCT: 0.51 (+0.01), JNJ: 99.53 (+1.13), OREX: 4.70 (+0.04), FCSC: 5.40 (+0.27), NVIV: 14.01 (-1.01), GILD: 113.74 (+0.38), GWPH: 125.86 (+5.39), CTSO: 6.20 (+0.40), ACHN: 8.68 (+0.14), RMD: 57.05 (+0.28), SNY: 51.49 (+2.71), PBYI: 106.25 (-2.12)
Dendrimers Coming Of Age: Starpharma's Star Is Rising
Keith Williams - at Seeking Alpha - Fri May 15, 11:05AM CDT
PFE: 34.36 (+0.50), AZN: 66.45 (+1.90), LLY: 88.29 (+0.81), SNY: 51.49 (+2.71)
How Not To Handle Your Clinical Data
Derek Lowe - Seeking Alpha - Wed May 13, 11:59AM CDT
We turn now to Orexigen (NASDAQ: OREX ), one of the small companies trying to make headway in the obesity market. Earlier this year, a patent application from them published, claiming that their drug ( Contrave , a sustained release formulation...
OREX: 4.70 (+0.04)
Takeda - Orexigen partnership on the rocks after CV outcomes study halted
Seeking Alpha - at Seeking Alpha - Wed May 13, 6:25AM CDT
OREX: 4.70 (+0.04)
First patient dosed in Takeda's Phase 3 study of proteasome inhibitor in myeloma
Seeking Alpha - at Seeking Alpha - Tue May 12, 6:31AM CDT
Infinity Pharmaceuticals: Analyzing The Impact Of Repurchasing Takeda's Royalty Agreement
Jonathan Liu - at Seeking Alpha - Mon Apr 13, 7:50PM CDT
INFI: 10.19 (+0.23), ABBV: 69.23 (+1.26)
Takeda Pharma offers $2.2B to settle Actos cases
Seeking Alpha - at Seeking Alpha - Wed Apr 01, 6:31AM CDT
LLY: 88.29 (+0.81)
Infinity Pharma buys out royalty obligations from Takeda for $52.5M
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 10:30AM CDT
ABBV: 69.23 (+1.26), INFI: 10.19 (+0.23)
Why ImmunoGen Inc. is Soaring Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 23, 2:25PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. ImmunoGen, What's happening: Shares in ...
IMGN: 14.44 (+0.25), AMGN: 154.10 (+2.79), LLY: 88.29 (+0.81)
Takeda licenses ImmunoGen's ADC technology to develop cancer therapeutics
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 6:47AM CDT
IMGN: 14.44 (+0.25)
Orexigen torpedoes shorts on news of Contrave's heart safety benefit
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 12:03PM CST
OREX: 4.70 (+0.04), VVUS: 2.15 (+0.02), ARNA: 4.29 (+0.04)
Amgen's Kyprolis beats Takeda's Velcade in head-to-head study
Seeking Alpha - at Seeking Alpha - Sun Mar 01, 10:53PM CST
AMGN: 154.10 (+2.79)
Heptares Takes Sosei Out Of Its Comfort Zone
EP Vantage - Seeking Alpha - Mon Feb 23, 2:37PM CST
It makes perfect sense for a small Japanese company to harbour expansion plans, but the private UK neuroscience player Heptares Therapeutics makes an unusual bedfellow for Sosei ( OTC:SOLTF ) , a group with a predominantly respiratory focus....
AZN: 66.45 (+1.90), NVS: 103.22 (+3.20)
Interim results positive for Takeda blood cancer med
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 6:17AM CST
Canada accepts Sucampo's NDS for constipation med
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 6:38AM CST
SCMP: 18.15 (+0.87)
AMAG and Takeda part ways on ferumoxytol
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 7:31AM CST
AMAG: 71.72 (+2.23)